BETHESDA, Maryland, February 19 /PRNewswire/ --
- New Methods Delivered to German Government in January
United BioSource Corporation's (UBC) director of global health economics has just delivered to the German government one of the most significant revisions of drug policy produced in Europe in more than a decade.
(Logo: http://www.newscom.com/cgi-bin/prnh/20070910/NEM007LOGO )
The 70-page report, commissioned last year by Germany's Institute for Quality and Efficiency In Healthcare (IQWiG), will be used by the German government to evaluate drugs and devices and to set prices and reimbursement levels for those products. The document is expected to be widely influential both inside and outside of Germany, the third largest pharmaceutical market in the world.
The director and main author of the report, Jaime Caro, MD, Senior Vice President of UBC, was selected by the German government to head the eight-member international panel because of his recognized authority in the design and implementation of cutting-edge modeling and analytic techniques for health technology assessments, particularly in determining the value and safety of medical products.
According to Dr. Caro, "It was an immense honor to lead such a distinguished panel in developing pioneering methods for economic evaluation. These methods will have a strong influence on the efforts of society to control health care costs. I am very glad that with my team of experienced professionals at UBC, we can work towards improving health outcomes."
Made public in Berlin on January 24, 2008 by IQWiG, the findings and recommendations of the expert panel, if accepted, will directly impact the pricing and reimbursement of pharmaceuticals, biologicals and medical devices in Germany, which has the largest population of any EU nation.
Dr. Caro recommends that companies with marketed products and products in development set up a process to assess where the pharmaceuticals fall under the new methods and "be prepared to defend their position, understanding that they might need additional data or other strategies."
The report is titled Methods for Assessment of the Relation of Benefits to Costs in the German Statutory Health Care System.
United BioSource Corporation (UBC) is a global pharmaceutical services organization that helps emerging and established life science companies develop and commercialize medical products. UBC specializes in offering new and innovative ways to study drugs and devices by offering expertise in science, strategy and execution.
UBC is headquartered in Bethesda, Maryland, with offices in the United States, Canada, Western Europe (including Cologne, Germany), Eastern Europe and South America. For more information, visit www.unitedbiosource.com or call +1-866-458-1096.
CONTACT: Tess Drahzal, +1-240-644-0420, info@unitedbiosource.com
Available Topic Expert(s): For information on the listed expert(s), click appropriate link. Jaime Caro, MD http://profnet.prnewswire.com/Subscriber/ExpertProfile.aspx?ei=73597
Web site: http://www.unitedbiosource.com
Tess Drahzal of United BioSource Corporation, +1-240-644-0420, info@unitedbiosource.com; Photo: NewsCom: http://www.newscom.com/cgi-bin/prnh/20070910/NEM007LOGO, AP Archive: http://photoarchive.ap.org, PRN Photo Desk, photodesk@prnewswire.com
Comments